Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial
Journal of Diabetes Investigation · 2024
DOI: 10.1111/jdi.14246 ↗At a glance
Randomisierte kontrollierte Studie in Journal of Diabetes Investigation, 2024. Written by Daisuke Ito and 10 co-authors. Institution: Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Pioglitazone, Thiophenes, Glucosides. Cited 24 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Aims/Introduction We conducted a 5 year post‐trial monitoring study of our previous randomized 24 week, open‐label, active‐controlled trial that showed beneficial effects of ipragliflozin on metabolic dysfunction‐associated steatotic liver disease (MASLD), identical to those of pioglitazone. Materials and Methods In our previous trial, 66 patients with MASLD and type 2 diabetes were randomly assigned to receive either ipragliflozin ( n = 32) or pioglitazone ( n = 34). Upon its conclusion, 61 patients were monitored for 5 years for outcome measures of MASLD, glycemic, and metabolic parameters. Differences between the two groups were analyzed at baseline, 24 weeks, and 5 years; changes in outcome measures from baseline were also evaluated.
Results
At 5 years, the mean liver‐to‐spleen attenuation ratio increased by 0.20 (from 0.78 ± 0.24 to 0.98 ± 0.20) in the ipragliflozin group and by 0.26 (from 0.76 ± 0.26 to 1.02 ± 0.20) in the pioglitazone group ( P = 0.363). Similarly, ipragliflozin and pioglitazone significantly improved serum aminotransferase, HbA1c, and fasting plasma glucose levels over 5 years. In the ipragliflozin group, significant reductions in body weight and visceral fat area observed at 24 weeks were sustained throughout the 5 years (−4.0%, P = 0.0075 and −7.6%, P = 0.045, respectively). Moreover, ipragliflozin significantly reduced the values of fibrosis markers (serum ferritin and FIB‐4 index), was well tolerated, and had a higher continuation rate for 5 years compared with pioglitazone.
Conclusions
Ipragliflozin and pioglitazone improved MASLD and glycemic parameters over 5 years. In the ipragliflozin group, significant reductions in body weight and visceral fat mass persisted for 5 years.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.
- Department of Internal Medicine, Ogawa Red Cross Hospital, Saitama, Japan.
- Satsuki Medical Clinic, Saitama, Japan.
- Department of Gastroenterology and Hepatology, Saitama Medical University, Saitama, Japan.
- Department of Diabetes and Endocrinology, Higashiyamato Hospital, Tokyo, Japan.
ORCID profiles: Daisuke Ito, Yoshihito Uchida, Akira Shimada
Cite
APA
Ito, D., Shimizu, S., Haisa, A., Yanagisawa, S., Inoue, K., Saito, D., Sumita, T., Yanagisawa, M., Uchida, Y., Inukai, K., & Shimada, A. (2024). Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14246
Vancouver
Ito D, Shimizu S, Haisa A, Yanagisawa S, Inoue K, Saito D, et al. Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14246
BibTeX
@article{Ito2024,
author = {Ito, Daisuke and Shimizu, Satoshi and Haisa, Akifumi and Yanagisawa, Shinnosuke and Inoue, Kazuyuki and Saito, Daigo and Sumita, Takashi and Yanagisawa, Morifumi and Uchida, Yoshihito and Inukai, Kouichi and Shimada, Akira},
title = {Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial},
journal = {Journal of Diabetes Investigation},
year = {2024},
doi = {10.1111/jdi.14246}
}
EUVIMED